Free Trial
ASX:PAR

Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis

Paradigm Biopharmaceuticals logo

About Paradigm Biopharmaceuticals Stock (ASX:PAR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.81 million shs
Average Volume
N/A
Market Capitalization
$196.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Receive PAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PAR Stock News Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Paradigm Biopharmaceuticals Ltd. (PBIGF) Receives a Buy from Bell Potter
See More Headlines

PAR Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Computer Hardware
Current Symbol
ASX:PAR
CIK
N/A
Fax
N/A
Employees
1,480
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,650,000.00
Net Margins
-89,138.58%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$79,224.00
Price / Cash Flow
6.44
Book Value
A$0.08 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$196.66 million
Optionable
Not Optionable
Beta
0.94
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (ASX:PAR) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners